ESTRO 2024 - Abstract Book

S1065

Clinical - Gynaecology

ESTRO 2024

metastasis-free survival) measured by the Kaplan–Meier method. The secondary endpoints were the response rate post-NACT and 12 weeks post-CCRT, as well as adverse events.

Results:

After a median follow-up of 42 months, 12 patients died: 9 due to disease progression, 1 due to treatment complication (pelvic fistulization) and 2 due to other causes. Thirty patients (83.3%) had pelvic and/or para-aortic lymph node involvement and nineteen (52.7%) of them received extended-field radiotherapy. The 4-year OS rate was 66%, 4-year PFS rate was 62.2% and the 4-year DMFS rate is 79.4%. The complete and partial response rates were 11.1% and 77.7%, post-NACT. Twelve weeks after treatment completion, the complete response rate was 80.5%, whereas the total response rate (complete and partial response) was 91.6%. The most common early adverse events were myelosuppression and diarrhea. Grade 3/4 toxicities were 25% during NACT (hematological: 16.6%, non-hematological: 8.3%) and 51% during CCRT (hematological: 38%, non-hematological: 13.8%). Late toxicities were mostly low grade, with only two patients (5.5%) experiencing grade 3/4 toxicity.

Conclusion:

Our institutional experience suggests that the use of NACT prior to standard CCRT produced favourable outcomes, though the long-term survival benefits compared to CCRT alone remain unclear. It can be used as an alternative to standard of care in places where there is a long wait for definitive treatment without compromising the outcome.

Keywords: cervical cancer, neoadjuvant chemotherapy

References:

1. Small W, Bacon MA, Bajaj A, et al. Cervical cancer: a global health crisis. Cancer. 2017;123:2404–12.

2. Tharavichitkul E, Lorvidhaya V, Kamnerdsupaphon P, et al. Combined chemoradiation of cisplatin versus carboplatin in cervical carcinoma: a single institution experience from Thailand. BMC Cancer. 2016;16:501.

2192

Digital Poster

TREATMENT WITH RE-IRRADIATION FOR CERVICAL CANCER RECURRENCES

Ana Carolina Ahumada Pamanes 1 , Salvador Gutierrez Torres 2 , Sandra Ileana Perez Alvarez 2 , Guadalupe Elizabeth Trejo Duran 2 , Aida Mota Garcia 2 1 Centro Universiotario Contra el Cáncer, Hospital Universitario, Radioterapia, Monterrey, Mexico. 2 Instituto Nacional de Cancerologia, Radioterapia, Ciudad de México, Mexico

Purpose/Objective: